ArticleDiscover oncology2025
Unraveling the role of blood cell perturbation responses in lung cancer by Mendelian randomization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung cancer remains the leading cause of cancer-related deaths globally. Emerging evidence indicates a potential link between blood cell perturbation responses and various diseases. Further investigation into the connection between these responses and lung cancer could provide valuable insights into its biological behavior and improve strategies for risk stratification.
methodsThis study employs two-sample mendelian randomization, incorporating lung cancer data from the IEU OpenGWAS project, as well as hematopoietic perturbation response data, to investigate the causal relationships between hematopoietic perturbation responses and lung cancer. This study also differentiated between subtypes: small cell lung carcinoma, adenocarcinoma, and squamous cell carcinoma. The primary analytical method was the inverse variance weighted (IVW) approach. Egger intercept analysis, abnormal MR-PRESSO test, Cochran Q, and leave one out analysis were also employed as multiple sensitivity analyses to assess the robustness of the results.
results18 blood cell perturbation responses were significantly associated with lung cancer and its subtypes, including 10 protective factors and 8 risk factors. In addition, reverse Mendelian randomization analysis identified 12 blood cells with reverse causal relationships with cancer, comprising 11 inhibitory factors and 1 promoting factor.
conclusionsOur findings demonstrate a potential causal relationship between lung cancer and blood cell perturbation responses, providing a new perspective for diagnosing and treating lung cancer. However, further studies are needed to elucidate the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.